Medical Oncology

Doç. Dr. Furkan Sarıcı

Doctor and researcher Medicana International Ankara Ankara
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: medicana.com.tr.

  • Meme Kanseri
  • Kolan kanseri
  • Akciğer Kanseri
  • Lenfoma

CV

Education and experience

From source

Experience

  • 2006-2011Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıklarımedicana.com.tr
  • 2011-2015Hacettepe Üniversitesi Tıp Fakültesi Onkolojimedicana.com.tr
  • 2015-2016SBÜ Konya Eğitim Arşt.Hastanesimedicana.com.tr
  • 2016-2018Medicana Internatıonal Ankara Hastanesimedicana.com.tr
  • 2018-2020İstinye Üniversitesi Tı Fklt. – Medical Park Trabzon Hastanesimedicana.com.tr

Education

  • EducationHacettepe Üniversitesi Tıp Fakültesimedicana.com.tr
  • EducationHacettepe Üniversitesi Tıp Fakültesimedicana.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologymedicana.com.trFrom source
  • Department name at the sourceMedikal Onkolojimedicana.com.trFrom source
  • InstitutionMedicana International Ankaramedicana.com.trFrom source
  • Publications13 publicationsmedicana.com.tr profile pageFrom source
  • Last synchronised7 November 2026 03:18https://www.medicana.com.tr/hekim-detay/12004/furkan-saricimedicana.com.tr

Scientific work

Publications

13 publications

  1. 1)Sarici F, Sunar V, Aksoy S. The Frequency and Determinants of Metabolic Syndrome in Operated Patients with Stage I-III Breast Cancer. International Journal of Hematology and Oncology 2020; 30(1):1-10.

    Source: medicana.com.tr profile page

  2. 2)Sarici F, Babacan T, Buyukhatipoglu H et al. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience. J BUON.2016;21(4):826-31.

    Source: medicana.com.tr profile page

  3. 3)Sarici F, Kertmen N, Aslan A, Tasdemir V, Babacan T, Kilickap S, Ozdemir E, Barista İ, Turker A, Kars A.

    Source: medicana.com.tr profile page

  4. Anthracyclin – Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75. International Journal of Hematology and Oncology 2016; 26(2):089-095.

    Source: medicana.com.tr profile page

  5. 4)Ates O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakas Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundag K.Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. J BUON. 2016;21(2):375-81.

    Source: medicana.com.tr profile page

  6. 5)Ates O, Soylu C, Babacan T, Sarici F, Kertmen N, Allen D, Sever AR, Altundag K.Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. Springerplus. 2016;19(5):486.

    Source: medicana.com.tr profile page

  7. 6)Sarici F, Babacan T, Altudag K, Balakan O, GulluI. Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents. J BUON.2013;18(3):799.

    Source: medicana.com.tr profile page

  8. 7)Solak M, Turkoz FP, Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Sever AR, Altundag K. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality. J BUON.2015;20(3):737-45.

    Source: medicana.com.tr profile page

  9. 8)Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundag K. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON.2015;20(1):50-6.

    Source: medicana.com.tr profile page

  10. 9)Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ates O, Aksoy S, Sever AR, Altundag K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori.2015;101(4):418-23.

    Source: medicana.com.tr profile page

View all 13 publications